Journal ArticleOPEN ACCESS

High Prescription Rate of Medications with Rifampin Drug-drug Interactions in Patients with Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?

Open Forum Infectious Diseases (2024) 11(11)
DOI: 10.1093/ofid/ofae582
3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.

Author supplied keywords

Cite

CITATION STYLE

APA

Mallarino-Haeger, C., Watson, A., Mahgoub, U., Francis, L., Heydari, M., Choudhary, M., … Schechter, M. C. (2024). High Prescription Rate of Medications with Rifampin Drug-drug Interactions in Patients with Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy? Open Forum Infectious Diseases, 11(11). https://doi.org/10.1093/ofid/ofae582

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free